sales@scalarmarketresearch.com  |   +1-800-213-5170  (U.S./ Canada Toll-free)  |  REGISTER |  SIGN IN

Home >> Reports >> orphan drugs market

report

Orphan Drugs Market, by Type (Biological Orphan Drugs, Non-Biological Orphan Drugs), Therapeutic Area (Oncology, Neurology, Hematology, Infectious Disease, Metabolic Disease, and Others) - Global Revenue, Trends, Growth, Share, Size and Forecast to 2022

HC170 November 2016 100 FREE 10% CUSTOMIZATION

Orphan Drugs Market is worth USD 111.87 billion in 2016 and is expected to reach USD 214.14 billion by 2022, at a CAGR of 11.43% from 2016 to 2022.

The global orphan drugs market report offers in-depth analysis of the market size (revenue), market share, major market segments, different geographic regions, forecast for the next five years, key market players, and premium industry trends. It also focuses on the key drivers, restraints, opportunities and challenges in the orphan drugs market.

KEY BENEFITS OF THE REPORT

  • In-depth analysis of the market segments that will showcase the greatest growth potential
  • Information about the technological advancements influencing the growth of the global market
  • Extensive analysis of the key players dominating the competitive landscape of this market

KEY PREMIUM INDUSTRY INSIGHTS

  • The primary reason for the growth of the orphan drugs market includes the government support from the developed as well as developing regions to develop the advanced orphan drugs. For instance, the U.S. Food and Drug Administration’s Office of Orphan Products Development (OOPD) department is specifically dedicated to driving the developments and evaluation of the orphan drugs, biologics, devices, or medical foods that can be useful for the treatment and diagnosis of the rare diseases.
  • The U.S. government also provides 50% of tax credit on the research and development expenses spent on orphan drugs development by companies.  These types of initiatives would, in turn, increase the investment in the orphan drug development, driving the growth of the orphan drugs market.
  • The increasing number of cases of the rare forms of cancers coupled with the innovations in biotechnology are also driving the growth of the orphan drugs market.
  • However, the low interest of the companies to develop the orphan drugs and the high costs of these drugs may hamper the market growth to some extent.

RESEARCH METHODOLOGY

The research methodology for Scalar Market Research’s orphan drugs market report utilizes a combination of top-down and bottom-up research formats. Our primary focus on continuous market tracking, rigorous fact-checking, data-triangulation, and multiple layers of quality control ensures high-quality data that can be leveraged for actionable research insights.

To know about the assumptions considered for the study, Download PDF Sample.

MARKET SEGMENTATION

This report analyzes the orphan drugs market by the following segments:

  • Orphan Drugs Market, by Type
    • Biological Orphan Drugs
    • Non-Biological Orphan Drugs
  • Orphan Drugs Market, by Therapeutic Area
    • Oncology
    • Neurology
    • Hematology
    • Infectious Disease
    • Metabolic Disease
    • Others

KEY MARKET PLAYERS

Key players in the orphan drugs market include:

  • Amgen, Inc
  • Alexion Pharmaceuticals
  • Pfizer, Inc
  • Celgene Corporation
  • Novartis International AG.
  • Shire, plc
  • Hoffman-La-Roche
  • BioMarin Pharmaceuticals, Inc

GEOGRAPHIC COVERAGE AND ANALYSIS

This granular market research report covers the following geographic regions in great detail:

Orphan Drugs Market

TRENDING RELATED REPORT

Biosimilars Market, by Product Types (Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins, Recombinant Peptides), Applications (Oncology, Blood Disorders, Infectious Diseases, Autoimmune Diseases, and Others) - Global Revenue, Trends, Growth, Share, Size and Forecast to 2022


  1. MARKET OVERVIEW
    1. Market Definitions
    2. Research Methodology
    3. Market Segmentation
    4. Assumptions
  2. EXECUTIVE SUMMARY
  3. MARKET DYNAMICS
    1. Drivers
    2. Restraints
    3. Opportunities
    4. Trends
  4. INDUSTRY ANALYSIS
    1. Industry Overview
    2. Regulatory Analysis
      1.  European Union
      2. U.S. FDA
      3. Other Countries
    3. Time to Entry Analysis
    4. Pipeline Analysis
    5. Pricing Analysis
  5. ORPHAN DRUGS MARKET, BY TYPE
    1. Market Overview
    2. Market Share Segmentation
    3. Revenue Segmentation
    4. Type
      1. Biological Orphan Drugs
      2. Non-Biological Orphan Drugs
  6. ORPHAN DRUGS MARKET, BY THERAPEUTIC AREA
    1. Market Overview
    2. Market Share Segmentation
    3. Revenue Segmentation
    4. Therapeutic Area
      1. Oncology
      2. Neurology
      3. Hematology
      4. Infectious Disease
      5. Metabolic Disease
      6. Others
  7. ORPHAN DRUGS MARKET, BY REGIONS
    1. Market Share Segmentation
    2. Revenue Segmentation
    3. North America
      1. By Regions
        1. U.S.
        2. Canada
      2. By Type
      3. By Therapeutic Area
    4. Europe
      1. By Regions
        1. Germany
        2. U.K
        3. France
        4. Italy
        5. Rest of Europe
      2. By Type
      3. By Therapeutic Area
    5. Asia-Pacific
      1. By Regions
        1. China
        2. India
        3. Australia
        4. Japan
        5. Singapore
        6. Rest of Asia-Pacific
      2. By Type
      3. By Therapeutic Area
    6. Rest of the World
      1. By Regions
        1. Latin America
        2. Middle East & Africa
      2. By Type
      3. By Therapeutic Area
  8. COMPETITIVE LANDSCAPE
    1. Market Share Analysis
    2. Market Positioning
  9. KEY MARKET PLAYERS
    1. Amgen, Inc
      1. Overview
      2. Key Strategies
      3. Recent Developments
    2. Alexion Pharmaceuticals
      1. Overview
      2. Key Strategies
      3. Recent Developments
    3. Pfizer, Inc
      1. Overview
      2. Key Strategies
      3. Recent Developments
    4. Celgene Corporation
      1. Overview
      2. Key Strategies
      3. Recent Developments
    5. Novartis International AG.
      1. Overview
      2. Key Strategies
      3. Recent Developments
    6. Shire, plc
      1. Overview
      2. Key Strategies
      3. Recent Developments
    7. Hoffman-La-Roche
      1. Overview
      2. Key Strategies
      3. Recent Developments
    8. BioMarin Pharmaceuticals, Inc
      1. Overview
      2. Key Strategies
      3. Recent Developments
  10. SCALAR 360 DEGREE MARKET PERSPECTIVE
  11. APPENDIX

 

LIST OF TABLES

Table 1.                Assumptions

Table 2.                Global Orphan Drugs Market Summary

Table 3.                Prevalence of Rare Diseases by Major Countries

Table 4.                List of Some of the Known Rare Diseases

Table 5.                Market Exclusivity for Orphan Drugs by Major Regions

Table 6.                Average Number of Patients in Clinical Trials

Table 7.                Market Attractiveness for Orphan Drugs Setup

Table 8.                Regulatory Analysis Snapshot

Table 9.                EMA Approved Orphan Drugs (2015 – 2016)

Table 10.              Orphan Drug Regulations in Other Countries

Table 11.              Time to Entry Analysis ( Standard Drugs vs. Orphan Drugs)

Table 12.              Average Time for FDA Approval

Table 13.              Orphan Drugs in Phase 3 Stage of the Development (2015)

Table 14.              Pricing with respect to prevalence of rare disease

Table 15.              Average Price of Orphan Drugs by Type

Table 16.              Pricing of Top Orphan Drugs with Average Market Price (2015)

Table 17.              List of 10 Top Marketed Orphan Drugs (2015)

Table 18.              Global Orphan Drugs Market Size (US$ billion), By Type (2014 – 2022)

Table 19.              Global Biological Orphan Drugs Market Size (US$ billion), By Regions (2014 – 2022)

Table 20.              Global Non-Biological Orphan Drugs Market Size (US$ billion), By Regions (2014 – 2022)

Table 21.              Global Orphan Drugs Market Size (US$ billion), By Therapeutic Area (2014 – 2022)

Table 22.              Global Orphan Drugs Market for Oncology; Market Size (US$ billion) (2014 – 2022)

Table 23.              Global Orphan Drugs Market for Neurology, Market Size (US$ billion) (2014 – 2022)

Table 24.              Global Orphan Drugs Market for Haematology, Market Size (US$ billion) (2014 – 2022)

Table 25.              Global Orphan Drugs Market for Infectious Disease, Market Size (US$ billion) (2014 – 2022)

Table 26.              Global Orphan Drugs Market for Metabolic Disease, Market Size (US$ billion) (2014 – 2022)

Table 27.              Global Orphan Drugs Market for Other Diseases, Market Size (US$ billion) (2014 – 2022)

Table 28.              Orphan Drugs Market Prospects, by Geography (2016 – 2022)

Table 29.              Global Orphan Drugs Market Size (US$ billion), By Geography (2014 – 2022)

Table 30.              Global Orphan Drugs Market, Market Size (%), By Major Regions (2014 – 2022)

Table 31.              Orphan Drugs Market in North America, Market Size (US$ billion) (2014 – 2022)

Table 32.              Orphan Drugs Market in U.S., Market Size (US$ billion), (2014 – 2022)

Table 33.              Orphan Drugs Market in Canada, Market Size (US$ billion), (2014 – 2022)

Table 34.              Orphan Drugs Market in North America, Market Size (US$ billion), By Type (2014 – 2022)

Table 35.              Orphan Drugs Market in North America, Market Size (US$ billion), By Therapeutic Area (2014 – 2022)

Table 36.              Orphan Drugs Market in Europe, Market Size (US$ billion)

Table 37.              Orphan Drugs Market in Germany, Market Size (US$ billion), (2014 – 2022)

Table 38.              Orphan Drugs Market in U.K, Market Size (US$ billion), (2014 – 2022)

Table 39.              Orphan Drugs Market in France, Market Size (US$ billion), (2014 – 2022)

Table 40.              Orphan Drugs Market in Italy, Market Size (US$ billion), (2014 – 2022)

Table 41.              Orphan Drugs Market in Rest of Europe, Market Size (US$ billion), (2014 – 2022)

Table 42.              Orphan Drugs Market in Europe, Market Size (US$ billion), By Type (2014 – 2022)

Table 43.              Orphan Drugs Market in Europe, Market Size (US$ billion), By Therapeutic Area (2014 – 2022)

Table 44.              Orphan Drugs Market in Asia-Pacific, Market Size (US$ billion)

Table 45.              Orphan Drugs Market in China, Market Size (US$ billion), (2014 – 2022)

Table 46.              Orphan Drugs Market in India, Market Size (US$ billion), (2014 – 2022)

Table 47.              Orphan Drugs Market in Australia, Market Size (US$ billion), (2014 – 2022)

Table 48.              Orphan Drugs Market in Japan, Market Size (US$ billion), (2014 – 2022)

Table 49.              Orphan Drugs Market in South Korea, Market Size (US$ billion), (2014 – 2022)

Table 50.              Orphan Drugs Market in Rest of Asia-Pacific, Market Size (US$ billion), (2014 – 2022)

Table 51.              Orphan Drugs Market in Asia-Pacific, Market Size (US$ billion), By Type (2014 – 2022)

Table 52.              Orphan Drugs Market in Asia-Pacific, Market Size (US$ billion), By Therapeutic Area (2014 – 2022)

Table 53.              Orphan Drugs Market in Rest of the World (ROW), Market Size (US$ billion)

Table 54.              Orphan Drugs Market in Latin America, Market Size (US$ billion), (2014 – 2022)

Table 55.              Orphan Drugs Market in Middle East & Africa, Market Size (US$ billion), (2014 – 2022)

Table 56.              Orphan Drugs Market in Rest of the World (ROW), Market Size (US$ billion), By Type (2014 – 2022)

Table 57.              Orphan Drugs Market in Rest of the World (ROW), Market Size (US$ billion), By Therapeutic Area (2014 – 2022)

Table 58.              Revenue from Orphan Drugs (US$ billion) By Major Players (2014 & 2015)

Table 59.              Orphan Drugs Market Snapshot

Table 60.              Acronyms

 

LIST OF FIGURES

Figure 1.               Research Methodology

Figure 2.               Orphan Drugs Timeline

Figure 3.               Orphan Drugs by Stage of Development (2016)

Figure 4.               Orphan Drugs in Pipeline, by Therapeutic Area (2016)

Figure 5.               Global Orphan Drugs Market By Type: Market Size vs. Market Penetration (2015)

Figure 6.               Global Orphan Drugs Segment Share (%), By Type (2016 & 2022)

Figure 7.               Global Orphan Drugs Market Size (US$ billion), By Type (2016 & 2022)

Figure 8.               Global Biological Orphan Drugs Segment Share (%), By Regions (2016 & 2022)

Figure 9.               Global Biological Orphan Drugs Market Size (US$ billion), By Regions (2016 & 2022)

Figure 10.            Global Non-Biological Orphan Drugs Segment Share (%), By Regions (2016 & 2022)

Figure 11.            Global Non-Biological Orphan Drugs Market Size (US$ billion), By Regions (2016 & 2022)

Figure 12.            Market Attractiveness for Orphan Drugs, By Therapeutic (2016)

Figure 13.            Global Orphan Drugs Segment Share (%), By Therapeutic Area (2016 & 2022)

Figure 14.            Global Orphan Drugs Market Size (US$ billion), By Therapeutic Area (2016 & 2022)

Figure 15.            Global Orphan Drugs Market  for Oncology, Market Size (US$ billion) (2016 & 2022)

Figure 16.            Global Orphan Drugs Market  for Neurology, Market Size (US$ billion) (2015 & 2022)

Figure 17.            Global Orphan Drugs Market  for Haematology, Market Size (US$ billion) (2016 & 2022)

Figure 18.            Global Orphan Drugs Market  for Infectious Disease, Market Size (US$ billion) (2016 & 2022)

Figure 19.            Global Orphan Drugs Market for Metabolic Disease, Market Size (US$ billion) (2016 & 2022)

Figure 20.            Global Orphan Drugs Market  for Other Diseases; Market Size (US$ billion) (2016 & 2022)

Figure 21.            Global Orphan Drugs Market, Segment Share (%), By Geography (2016 & 2022)

Figure 22.            Orphan Drugs Market in North America, Snapshot

Figure 23.            Orphan Drugs Market in North America, Market Size (US$ billion) (2014-2022)

Figure 24.            Orphan Drugs Market in North America, Segment Share (%) By Regions, (2016 & 2022)

Figure 25.            Orphan Drugs Market in North America, Market Size (US$ billion), By Type, 2016 &2022

Figure 26.            Orphan Drugs Market in North America, Market Size (US$ billion), By Therapeutic Area (2016 & 2022)

Figure 27.            Orphan Drugs Market in Europe, Snapshot

Figure 28.            Orphan Drugs Market in Europe, Market Size (US$ billion) (2014-2022)

Figure 29.            Orphan Drugs Market in Europe, Segment Share (%) By Regions, (2016 & 2022)

Figure 30.            Orphan Drugs Market in Europe, Market Size (US$ billion), By Type (2016 & 2022)

Figure 31.            Orphan Drugs Market in Europe, Market Size (US$ billion), By Therapeutic Area (2016 & 2022)

Figure 32.            Orphan Drugs Market in Asia-Pacific, Snapshot

Figure 33.            Orphan Drugs Market in Asia-Pacific, Market Size (US$ billion) (2014 – 2022)

Figure 34.            Orphan Drugs Market in Asia-Pacific, Segment Share (%) By Regions, (2016 & 2022)

Figure 35.            Orphan Drugs Market in Asia-Pacific, Market Size (US$ billion), By Type (2016 & 2022)

Figure 36.            Orphan Drugs Market in Asia-Pacific, Market Size (US$ billion), By Therapeutic Area (2016 & 2022)

Figure 37.            Orphan Drugs Market in Rest of the World, Snapshot

Figure 38.            Orphan Drugs Market in Rest of the World, Market Size (US$ billion) (2014 – 2022)

Figure 39.            Orphan Drugs Market in Rest of the World, Segment Share (%) By Regions, (2016 & 2022)

Figure 40.            Orphan Drugs Market in Rest of the World, Market Size (US$ billion), By Type (2016 & 2022)

Figure 41.            Orphan Drugs Market in Rest of the World, Market Size (US$ billion), By Therapeutic Area (2016 & 2022)

Figure 42.            Market Share (%) of Major Players (2015)

Figure 43.            Market Positioning of Key Players

Please submit your enquiry below so our representative can get in touch with you
*
*
*
*
*
*
*

USA - CANADA TOLL FREE
+1-800-213-5170
EMAIL
sales@scalarmarketresearch.com

Benefits of Buying From Scalar

  • Unparalleled Expertise

    Our industry experts hold inimitable know-how across wide range of industry verticals

  • Assured Quality

    We deliver high-quality, real-time and data-driven industry insights to our clients

  • 24x7 Analyst Support

    We offer pre-purchase and post-purchase support from our industry experts

  • Privacy & Security

    All your personal information and confidential details are safe and secure with us